Russia slashes cancer care as defence spending hits post-Soviet record

How much is Russia proposing to cut federal funding for its national cancer programme in 2027?

Russia’s draft federal budget would cut the national cancer programme from 44.9 billion roubles in 2026 to 3.87 billion in 2027. The reduction is about 41 billion roubles, or nearly twelvefold. It matters because the programme has financed cancer centres, diagnostic equipment, and early screening across the country.

The proposed funding would cover mainly diagnostic and radiology equipment. However, specialised units in smaller towns and rural areas are expected to face cuts. This could widen the existing divide between cancer services in major federal centres and those available in outlying regions.

Officials say some costs will move to compulsory health insurance and other budget lines. Yet patient groups and experts question whether those mechanisms can fully replace federal support. Funding is planned to rise to 5.76 billion roubles in 2028 and 12.78 billion in 2029, but both amounts remain far below current levels.

How does the proposed cancer-programme budget compare with the 148.5 billion roubles allocated in 2025?

Russia allocated 148.5 billion roubles to the federal cancer programme in 2025. The proposed 2027 allocation is only 3.87 billion roubles. Comparing those figures shows a reduction of roughly 38 times over two years, a far steeper decline than the one-year cut from 44.9 billion roubles.

The difference represents a major change in the programme’s financial scale. Since its launch, federal money has supported diagnostic equipment, cancer centres, and early screening programmes. In 2027, the remaining funding is expected to focus mainly on diagnostic and radiology equipment, while specialised services may lose support.

The budget proposal includes partial recovery after the cut. Funding is projected to reach 5.76 billion roubles in 2028 and 12.78 billion in 2029. Even the 2029 figure would remain far below the 2025 allocation, leaving other systems to carry more costs.

What is Russia’s national cancer programme, and what has it normally paid for?

Russia’s national cancer programme is a federal project designed to strengthen cancer control. Its funding has supported the infrastructure needed to detect and treat cancer, rather than paying only for individual medicines. This makes its budget important for patients and medical providers across different regions.

The programme has normally paid for diagnostic equipment, cancer centres, and early screening programmes. Under the proposed 2027–2029 budget, the remaining money would go mainly to diagnostic and radiology equipment. Specialised units in smaller towns and rural areas, however, are expected to face cuts.

That pattern could deepen the gap between major federal centres and outlying regions. Officials say some costs may shift to compulsory health insurance and other budget lines. But patient organisations and experts question whether those routes can fully replace federal funding or protect equal access to cancer care.

Why is defence spending reaching about 35% of Russia’s federal expenditure, and how does that compare with the country’s post-Soviet history?

Russia’s draft 2027 budget sets defence spending at 17.1 trillion roubles, about 35% of all federal expenditure. The article links this exceptional share to more than four years of Moscow’s all-out war in Ukraine. Continued expansion of defence outlays has shifted national priorities away from civilian programmes.

The 35% figure is not just a large annual allocation. It is described as a post-Soviet record and the highest share since the Soviet Union collapsed. As defence takes more of the federal budget, healthcare and medical infrastructure are increasingly competing for a smaller share of available public money.

This context helps explain the proposed cancer-programme reduction. Civilian programmes, including cancer care, are taking a backseat to defence spending. The result could be less federal support for specialised services, especially outside major centres, even as patients already face rising medicine costs.

What could happen to cancer diagnosis and treatment in smaller towns and rural regions if federal funding is shifted to regional budgets and compulsory health insurance?

Smaller towns and rural areas could face reduced access to specialised cancer diagnosis and treatment. The proposed budget directs remaining federal money mainly toward diagnostic and radiology equipment, while specialised units in these areas face cuts. That threatens to widen an already significant gap with major federal centres.

The key mechanism is financial shifting. Officials say some costs will move from the federal cancer programme to compulsory health insurance and regional budgets. Those systems may continue paying for services, but their capacity differs across regions. Patient organisations and experts question whether they can fully offset the federal reduction.

As a result, the quality and availability of care could become more closely tied to regional financial strength. Patients may encounter longer journeys, fewer specialised services, or delays in treatment. The article also records rising out-of-pocket medicine purchases, suggesting households are already absorbing more pressure.

How are the compulsory health insurance system and other budget lines supposed to replace some of the funding being removed from the federal cancer programme?

The proposed budget does not present the federal reduction as the complete disappearance of every cancer-related expense. Officials say some costs will be transferred to the compulsory health insurance system, known as OMS, and to other budget lines. These routes are intended to keep services and purchases funded after federal programme money falls.

In practice, the shift changes who carries the financial responsibility. Regional budgets and the OMS would need to cover costs previously supported directly by the federal cancer project. The article does not give a detailed breakdown of which services will move or how much each system will receive.

Patient organisations and some experts therefore question whether the new mechanisms can fully compensate for the cut. They warn that relying more heavily on regional budgets links care quality to regional wealth. This concern is especially significant for smaller towns and rural areas, where specialised units already face reductions.

How do public budgets and health-insurance systems determine who pays for essential medicines when government procurement is delayed or regional funds are insufficient?

In the system described, government budgets and compulsory health insurance share responsibility for cancer medicines and care. Federal or regional authorities can fund procurement, while the OMS system supports large-scale medicine purchases. Russia’s law guarantees cancer patients free access to the medicines they need, including drugs on the essential-medicines list.

The pressure appears when procurement is delayed or regional budgets cannot provide enough stock. Patients then buy medicines independently, even though most of those drugs should be free. The Movement Against Cancer found that roughly one in every six or seven packs was bought out of pocket between 2019 and 2025. Most purchases involved generics, not optional expensive choices.

This means the formal payer and the practical payer can diverge. In 2025, households spent 11.4 billion roubles on anti-tumour drugs, while the government bought 32.8 million packs worth 336 billion through OMS. Rising household spending suggests gaps remain despite substantial public procurement.

Key Facts:

📌 Proposed 2027 cancer-programme funding is 3.87 billion roubles.

📌 Funding falls from 44.9 billion roubles the previous year.

📌 The programme’s 2027 budget is nearly twelve times smaller.

📌 The programme received 148.5 billion roubles in 2025.

📌 The proposed 2027 budget is 3.87 billion roubles.

📌 Federal spending would fall roughly 38-fold in two years.

📌 The programme has funded diagnostic equipment and cancer centres.